Clover Biopharmaceuticals, Ltd. (HKG:2197)
Hong Kong · Delayed Price · Currency is HKD
2.840
+0.090 (3.27%)
At close: Mar 27, 2026
Revenue by Segment
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
|---|
Research, Development, Manufacturing & Commercialization of Innovative Vaccines | 38.42M | 39.26M | - | - | | |
Research, Development, Manufacturing & Commercialization of Innovative Vaccines Growth | -2.13% | - | - | - | | |
| 38.42M | 39.26M | - | - | | |
| -2.13% | - | - | - | | |
Revenue by Geography
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
|---|
| 35.18M | 39.26M | - | - | | |
| -10.39% | - | - | - | | |
| 3.24M | - | - | - | | |
| 38.42M | 39.26M | - | - | | |
| -2.13% | - | - | - | | |
Source: S&P Global Market Intelligence.
